| (90) Yttrium Ibritumomab Tiuxetan as first line freatment for follicular lymphoma. 24 months follow up data from an international phase II clinical trial C Scholz, A Pinto, W Linkesch, O Linden, A Viardto, U Keller, G Hess, ... Onkologie 34, 270-270, 2011 | | 2011 |
| (R-) DHAP vs.(R-) IEV as salvage treatment for relapsed or refractory B-cell NHL: comparison of response rates, stem cell mobilisation and toxicity B Dengler, A Muller, U Keller, C Peschel, J Duyster, H Menzell Bone Marrow Transplantation 43 (S1), S211-S211, 2009 | | 2009 |
| [177Lu] pentixather: comprehensive preclinical characterization of a first CXCR4-directed endoradiotherapeutic agent M Schottelius, T Osl, A Poschenrieder, F Hoffmann, S Beykan, ... Theranostics 7 (9), 2350, 2017 | 101 | 2017 |
| [18F]FLT is superior to [18F]FDG for predicting early response to antiproliferative treatment in high-grade lymphoma in a dose-dependent manner N Graf, K Herrmann, B Numberger, D Zwisler, M Aichler, A Feuchtinger, ... European journal of nuclear medicine and molecular imaging 40, 34-43, 2013 | 39 | 2013 |
| [68Ga] Pentixafor: A Novel PET Tracer for Imaging CXCR4 Status in Patients with Multiple Myeloma K Philipp-Abbrederis, K Herrmann, M Schottelius, M Eiber, C Gerngroß, ... Blood, The Journal of the American Society of Hematology 124 (21), 2014-2014, 2014 | 4 | 2014 |
| [Ga-68] CPCR4. 2-PET for Imaging of CXCR4-Chemokine Receptors opens a new and exciting field of clinical research H Wester, U Keller, AB Beer, M Schottelius, F Hoffmann, H Kessler, ... EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 40, S152-S152, 2013 | 2 | 2013 |
| 668P Comprehensive analysis of the tumor immune microenvironment (TIM) in advanced adenoid cystic (ACC) and non-adenoid cystic salivary gland cancers (SGC) DT Rieke, E Blanc, B Von der Emde, I Piwonski, F Klauschen, ... Annals of Oncology 33, S848, 2022 | | 2022 |
| 875P Proteomic and phosphoproteomic profiling of HNSCC and the role of CDKs as potential drug targets K Klinghammer, M Keziban, I Tinhofer-Keilholz, U Keilholz, U Keller, ... Annals of Oncology 34, S564, 2023 | | 2023 |
| 90-yttrium-ibritumomab tiuxetan as first-line treatment for follicular lymphoma: updated efficacy and safety results at an extended median follow-up of 9.6 years K Rieger, R De Filippi, O Lindén, A Viardot, G Hess, K Lerch, ... Annals of Hematology 101 (4), 781-788, 2022 | 13 | 2022 |
| 90Yttrium ibritumomab tiuxetan as first line treatment for follicular lymphoma. First results from an international phase II clinical trial CW Scholz, A Pinto, W Linkesch, O Linden, A Viardot, U Keller, G Hess, ... Blood 116 (21), 593, 2010 | 11 | 2010 |
| 90Yttrium-Ibritumomab Tiuxetan as first line treatment for follicular non-Hodgkin lymphoma. 5 year results from an international multicenter phase II clinical trial K Lerch, C Leng, A Pinto, W Linkesch, H Sill, O Linden, A Viardot, U Keller, ... Blood 128 (22), 1806, 2016 | 1 | 2016 |
| 90Yttrium-Ibritumomab-Tiuxetan as First-Line Treatment for Follicular Lymphoma: 30 Months of Follow-Up Data From an International Multicenter Phase II Clinical … CW Scholz, A Pinto, W Linkesch, O Lindén, A Viardot, U Keller, G Hess, ... Journal of clinical oncology 31 (3), 308-313, 2013 | 130 | 2013 |
| 925P Treatment discontinuation of immune checkpoint blockade in patients with head and neck squamous cell carcinoma experiencing complete or nearly complete remission K Klinghammer, B Heinze, P Ivanyi, M Pogorzelski, S Laban, J Raguse, ... Annals of Oncology 34, S583-S584, 2023 | | 2023 |
| A CD205-directed antibody drug conjugate–lymphoma precision oncology or sophisticated chemotherapy? DT Rieke, U Keller Haematologica 105 (11), 2504, 2020 | | 2020 |
| A diagnostic challenge of KIT p. V559D and BRAF p. G469A mutations in a paragastric mass S Habringer, J Ihlow, K Kleo, A Klostermann, M Schmidt, L Chai, ... The Oncologist, oyae137, 2024 | | 2024 |
| A genome-wide functional in vivo transposon screen identifies novel cancer genes involved in B-cell lymphoma M Schick, S Steidle, M Barenboim, R Maresch, K Kunz, L Schneider, ... ONCOLOGY RESEARCH AND TREATMENT 40, 109-109, 2017 | | 2017 |
| A genome-wide functional in vivo transposon screen identifies SENP6 as tumor suppressor of MYC-driven B cell lymphomagenesis M Schick, S Maurer, L Schneider, K Kunz, A Scherger, M Barenboim, ... | | 2018 |
| A new stromal cell dependent culture system for expansion of early human hematopoietic progenitor cells without need of exogenous growth factors. U Keller, KS Gotze, J Duyster, S Rose-John, C Peschel BLOOD 96 (11), 322B-322B, 2000 | | 2000 |
| A peculiar case of primary central nervous system T-cell lymphoma with indolent behavior D Wasilewski, M Janz, A Koch, A Rosenwald, U Keller, P Vajkoczy, ... Acta Neurologica Belgica 123 (2), 667-670, 2023 | | 2023 |
| A phase II trial to evaluate the combination of pixantrone and obinutuzumab for patients with relapsed aggressive lymphoma: Final results of the prospective, multicentre GOAL trial G Hess, A Hüttmann, M Witzens‐Harig, MH Dreyling, U Keller, R Marks, ... British Journal of Haematology 198 (3), 482-491, 2022 | 8 | 2022 |
